2021

Pillar Biosciences seeks to make precision medicine a first-line therapy for cancer patients

Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics, in response to emailed questions from MedCity News.  Why did you join Pillar Biosciences? I am incredibly impressed with the technology and the amazing team at Pillar that have done so much work to bring our oncoReveal™ Dx …

Pillar Biosciences seeks to make precision medicine a first-line therapy for cancer patients Read More »

Pillar Biosciences to Collaborate with Labcorp on Precision Genomic Cancer Testing Using Next-Generation Sequencing

NATICK, Mass.–(BUSINESS WIRE)– Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics company, today announced that it has entered into an agreement with Labcorp (NYSE:LH), a leading global life sciences company, to provide genomic testing for people with cancer. Under the agreement, Pillar Biosciences will provide the oncoReveal™ Essential Myeloproliferative Neoplasm (MPN) panel. Using …

Pillar Biosciences to Collaborate with Labcorp on Precision Genomic Cancer Testing Using Next-Generation Sequencing Read More »

Pillar Biosciences Announces Appointment of Randy Pritchard as Chief Executive Officer

NATICK, Mass. & SHANGHAI–(BUSINESS WIRE)– Pillar Biosciences, an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, today announced the appointment of Randy Pritchard as Chief Executive Officer. The company’s founder, industry veteran and renowned scientific innovator, Gang Song, Ph.D., will transition to the role of Chairman of the Board, where he will be responsible …

Pillar Biosciences Announces Appointment of Randy Pritchard as Chief Executive Officer Read More »

XING Genomic Services receives NATA accreditation for Pillar Biosciences HRD Gene Panel Enabling Cost-Effective PARPi-response Prediction

Brisbane, Australia–XING Genomic Services, a subsidiary of XING Technologies, is pleased to announce that they have received NATA accreditation effective from July 2021 to offer clinical cancer genetic testing using the Pillar Biosciences HRD (homologous recombination deficiency) assay. This test identifies cancer patients that have tumours with impaired DNA repair capability, making them more likely …

XING Genomic Services receives NATA accreditation for Pillar Biosciences HRD Gene Panel Enabling Cost-Effective PARPi-response Prediction Read More »

Pillar Biosciences Receives Premarket Approval from FDA for its oncoReveal™ Dx Lung and Colon Cancer Assay

NATICK, Mass. & SHANGHAI–(BUSINESS WIRE)– Pillar Biosciences, an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, today announced the U.S. Food and Drug Administration (FDA) has given Premarket Approval (PMA) to its oncoReveal™ Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the qualitative detection of somatic mutations in DNA derived from …

Pillar Biosciences Receives Premarket Approval from FDA for its oncoReveal™ Dx Lung and Colon Cancer Assay Read More »

Pillar Biosciences appoints Dr. Eric Lai to its Board of Directors

NATICK, Mass. & SHANGHAI–(BUSINESS WIRE)–Pillar Biosciences, an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, today announced the appointment of Eric Lai, Ph.D. to the Board of Directors. Dr. Lai brings more than 20 years of experience in drug and IVD molecular diagnostic development to the team at Pillar Biosciences. Dr. Lai was previously …

Pillar Biosciences appoints Dr. Eric Lai to its Board of Directors Read More »